Novo Nordisk (NVO) shares fell 2.1% in early U.S. trading on Tuesday following reports that the company reduced the direct price of Wegovy and Ozempic to $349 per month (with an introductory dose priced at $199). The move comes after an agreement to expand accessibility in the U.S. Meanwhile, Eli Lilly (LLY) also lowered the price of Zepbound, with its shares rising 0.6% in early trading.